# First-line Chemotherapy Followed by Toripalimab Combined With Anlotinib for Maintenance in ES-SCLC

> **NCT04363255** · PHASE2 · UNKNOWN · sponsor: **Taizhou Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Small Cell Lung Carcinoma

## Interventions

- **DRUG:** Etoposide Injection
- **DRUG:** Carboplatin Injection
- **DRUG:** Cisplatin injection
- **DRUG:** Toripalimab
- **DRUG:** Anlotinib hydrochloride

## Key facts

- **NCT ID:** NCT04363255
- **Lead sponsor:** Taizhou Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-05-01
- **Primary completion:** 2022-12-31
- **Final completion:** 2023-03-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2020-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04363255

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04363255, "First-line Chemotherapy Followed by Toripalimab Combined With Anlotinib for Maintenance in ES-SCLC". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04363255. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*